As of Oct 23
| +0.30 / +5.61%|
The 3 analysts offering 12-month price forecasts for Adamis Pharmaceuticals Corp have a median target of 9.50, with a high estimate of 13.00 and a low estimate of 7.00. The median estimate represents a +68.14% increase from the last price of 5.65.
The current consensus among 3 polled investment analysts is to Buy stock in Adamis Pharmaceuticals Corp. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.